Thousand Oaks Biopharmaceutical Group has signed a joint venture agreement with a Korean biotech company in which they will boost serum-free cell culture media production, the companies said on Wednesday.
Cell culture media, a liquid or gel designed to support microorganism growth for lab use, will be developed to meet commercial demand on an international scale, according to venture terms.
T.O. Bio’s subsidiary, JS Biosciences, will play an integral role in the venture as the current leading cell culture media supplier to China.
The deal is with WSG Group, and the venture will focus on building a cell culture media production center in Korea with “significant capacity” this year, the companies said in a statement. The center will be Korea’s first local company for cell culture media, with the ability to produce thousands of kilograms in batch capacity.